World ADC 2024 Conference in San Diego

Join us at the upcoming World ADC 2024 Conference where our experts will be available to discuss how we can support your ADC development. Our expertise in antibody-drug conjugation (ADC) ensures you receive the high-quality service offers you need to advance your projects.

Target Selection Challenges

We use NGS/AI-based TAA discovery and selection, patient-derived tumor/normal tissue biobanks, organoids, and PDX models, with integrated bioinformatics and biomarker discovery.

Antibody Generation Complexity

Comprehensive antibody generation services, including antigen design and production, hybridoma generation, antibody screening (binding, ADCC, internalization), and deep phase screening for lead optimization. We also offer small molecule integration to enhance the therapeutic potential of antibody-drug conjugates, expanding the options for optimized ADC strategies.

ADC Development Bottlenecks

Crown provides advanced ADC development with site-specific conjugation techniques to optimize linker payloads, along with bioconjugation, physicochemical characterization, DAR, and endotoxin testing to ensure optimal drug performance. Additionally, mass spectrometry analysis is available to precisely assess pharmacokinetics (PK) and drug-to-antibody ratio (DAR), providing reliable data for informed decision-making in development.

Mechanism of Action (MoA) Uncertainty

Crown delivers Mechanism of Action (MoA) insights, allowing for deeper understanding of how monoclonal antibody therapies interact with cancer cells, which enhances their targeting effectiveness.

In Vitro Efficacy Uncertainty

In vitro biological characterization services, including model selection based on gene/protein expression, antigen binding, internalization studies, cytotoxicity screening in 2D/3D cell lines and organoids, as well as co-cultures with immune cells for bystander effect testing.

Translating In Vitro Success to In Vivo Models

Crown offers in vivo pharmacology services, including model selection for efficacy testing, PDX models, CDX/xenograft models with imaging, and efficacy/bystander effect testing. It also provides biomarker validation, proteomics, and combination studies with IO therapies. Moreover, access to the world’s largest collection of well-characterized patient-derived models, including organoids, PDX, syngeneic, pre-treated, and resistant models, accelerates ADC development by offering robust and diverse testing options."

Meet the Team